Evaluation of the Safety and Efficacy of the CardioPulseTM PuLsed fiEld Ablation SystEm in Patients With Paroxysmal Atrial Fibrillation (PLEASE-AF Study)

Inclusion Criteria: 1. Patients aged 18 to 75 years old; 2. Patients diagnosed with symptomatic paroxysmal atrial fibrillation: At least 1 ECG or rhythm monitoring documented AF episode within 12 months prior to enrollment. 3. Ineffective or intolerant of at least one antiarrhythmic drug; 4. Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol. Exclusion Criteria: 1. AF secondary to electrolyte imbalance, thyroid disease, or reversible cause; 2. Persistent or long-standing persistent AF; 3. Previous surgery or catheter ablation for AF; 4. Participant known to require ablation outside the pulmonary vein or in cavotricuspid isthmus region (such as atrioventricular reentrant tachycardia, atrioventricular nodalreentry tachycardia, atrial tachycardia, atrial flutter, ventricular tachycardia and Wolff-Parkinson-White syndrome); 5. Previous valve repair, replacement or artificial valve implantation; previous atrial septal defect closure, patent foramen ovale closure cardiac intervention or surgery; 6. Previous left atrial appendage closure; 7. Any myocardial infarction (MI), coronary artery bypass grafting (CABG) procedure or percutaneous coronary intervention (PCI) during the 6-month interval preceding the consent date; 8. Any carotid artery stent implantation or endarterectomy within the previous 6 months; 9. Left atrial diameter≥50 mm (anteroposterior); 10. LVEF \<40% on admission, or NYHA class III and IV; 11. Presence of implanted ICD, CRT, permanent pacemaker, or any type of implantable device 12. Documented active thrombus in the left atrium or atrial appendage on imaging; 13. Rheumatic heart disease; 14. Uncontrollable high blood pressure; 15. Hypertrophic cardiomyopathy, myocardial thickening was significantly greater than or equal to 15mm; 16. Frequent premature ventricular beats; 17. Documented thromboembolic event (including TIA) within the past 6 months; 18. Presence of intramural thrombus, tumor or other abnormality that precludes vascular access or catheter manipulation; 19. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gas or severe breathing difficulties; 20. Anticoagulation contraindications, and history of blood clotting or bleeding abnormalities; 21. Patients with acute systemic infection; 22. Serum creatinine is more than twice the upper normal limit, or have a history of kidney dialysis; 23. Women who are pregnant and/or breast feeding or unable to use contraception during the trial; 24. Enrollment in another clinical trial evaluating other devices or drugs during the same period; 25. Life expectancy less than 12 months (such as patients with advanced cancer); 26. Abnormalities or diseases that the investigator considers to be excluded from the study's coverage.